Wanbury Ltd
Incorporated in 1988, Wanbury Ltd is in the business of pharmaceutical and related activities, including research[1]
- Market Cap ₹ 922 Cr.
- Current Price ₹ 281
- High / Low ₹ 330 / 154
- Stock P/E 21.5
- Book Value ₹ 18.1
- Dividend Yield 0.00 %
- ROCE 34.9 %
- ROE 70.0 %
- Face Value ₹ 10.0
Pros
- Company has delivered good profit growth of 29.9% CAGR over last 5 years
Cons
- Stock is trading at 15.5 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
- The company has delivered a poor sales growth of 10.3% over past five years.
- Tax rate seems low
- Promoters have pledged or encumbered 76.7% of their holding.
- Company's cost of borrowing seems high
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Sep 2014 18m | Mar 2015 6m | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
661 | 250 | 420 | 432 | 370 | 391 | 367 | 392 | 511 | 485 | 557 | 600 | 630 | |
637 | 228 | 387 | 414 | 438 | 375 | 344 | 374 | 475 | 459 | 484 | 523 | 542 | |
Operating Profit | 25 | 21 | 33 | 19 | -68 | 16 | 23 | 18 | 36 | 26 | 73 | 76 | 88 |
OPM % | 4% | 9% | 8% | 4% | -18% | 4% | 6% | 5% | 7% | 5% | 13% | 13% | 14% |
-78 | 6 | 0 | 90 | 76 | 9 | 84 | 2 | 77 | -3 | 26 | 3 | 5 | |
Interest | 48 | 19 | 32 | 36 | 31 | 40 | 33 | 23 | 21 | 21 | 29 | 37 | 37 |
Depreciation | 23 | 5 | 9 | 10 | 10 | 10 | 10 | 10 | 11 | 12 | 13 | 13 | 14 |
Profit before tax | -125 | 4 | -7 | 62 | -32 | -25 | 65 | -12 | 81 | -10 | 56 | 30 | 42 |
Tax % | 2% | 28% | 0% | 1% | -1% | -1% | 0% | 2% | -0% | 1% | 1% | -3% | |
-128 | 3 | -7 | 62 | -32 | -25 | 64 | -13 | 81 | -10 | 56 | 31 | 43 | |
EPS in Rs | -63.95 | 1.60 | -3.58 | 26.71 | -13.49 | -10.48 | 25.79 | -5.04 | 24.94 | -3.18 | 17.09 | 9.32 | 13.10 |
Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | 9% |
5 Years: | 10% |
3 Years: | 5% |
TTM: | 12% |
Compounded Profit Growth | |
---|---|
10 Years: | 25% |
5 Years: | 30% |
3 Years: | 75% |
TTM: | 60% |
Stock Price CAGR | |
---|---|
10 Years: | 16% |
5 Years: | 48% |
3 Years: | 67% |
1 Year: | 21% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
Last Year: | 70% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Sep 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 20 | 20 | 20 | 23 | 24 | 24 | 25 | 25 | 33 | 33 | 33 | 33 |
Reserves | -212 | -214 | -209 | -176 | -208 | -233 | -168 | -181 | -56 | -66 | -5 | 26 |
389 | 381 | 362 | 300 | 250 | 260 | 190 | 192 | 100 | 95 | 116 | 177 | |
209 | 209 | 215 | 265 | 207 | 236 | 232 | 253 | 276 | 241 | 199 | 178 | |
Total Liabilities | 406 | 396 | 388 | 412 | 273 | 286 | 279 | 289 | 353 | 304 | 343 | 414 |
174 | 164 | 180 | 186 | 178 | 172 | 164 | 167 | 167 | 167 | 167 | 201 | |
CWIP | 13 | 19 | 14 | 10 | 10 | 9 | 14 | 11 | 2 | 2 | 3 | 5 |
Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
219 | 213 | 193 | 216 | 84 | 105 | 101 | 111 | 183 | 135 | 174 | 208 | |
Total Assets | 406 | 396 | 388 | 412 | 273 | 286 | 279 | 289 | 353 | 304 | 343 | 414 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Sep 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
68 | 40 | 43 | 43 | 32 | 30 | 44 | 17 | 41 | 20 | 4 | 26 | |
-6 | -5 | -20 | -13 | -1 | -3 | 64 | 8 | 1 | -9 | -17 | -51 | |
-71 | -30 | -28 | -27 | -33 | -27 | -108 | -17 | -29 | -32 | 15 | 26 | |
Net Cash Flow | -9 | 5 | -5 | 3 | -2 | -0 | -0 | 7 | 13 | -21 | 2 | 1 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Sep 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 57 | 144 | 65 | 71 | 29 | 41 | 50 | 32 | 45 | 52 | 59 | 70 |
Inventory Days | 42 | 103 | 69 | 63 | 27 | 36 | 25 | 41 | 60 | 26 | 43 | 47 |
Days Payable | 113 | 301 | 172 | 260 | 174 | 209 | 253 | 221 | 218 | 179 | 196 | 172 |
Cash Conversion Cycle | -14 | -55 | -38 | -125 | -118 | -131 | -177 | -148 | -113 | -101 | -94 | -55 |
Working Capital Days | -44 | -140 | -123 | -185 | -277 | -254 | -236 | -251 | -153 | -152 | -40 | 4 |
ROCE % | 4% | 12% | 57% | -1% | 26% | 31% | 27% | 46% | 21% | 61% | 35% |
Documents
Announcements
- Register Of Members And Share Transfer Books Of The Company Will Remain Closed From Friday, 12Th September, 2025 To Thursday, 18Th September, 2025 (Both Days Inclusive) For The Purpose Of Annual General Meeting 11h
- Announcement under Regulation 30 (LODR)-Newspaper Publication 1d
- Annual Report 2024-25 And Notice Of The 37Th Annual General Meeting Of Wanbury Limited. 2d
- Reg. 34 (1) Annual Report. 2d
- Announcement under Regulation 30 (LODR)-Newspaper Publication 23 Aug
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from nse
Business Overview:[1]
WL is a pharmaceutical company with a presence in the API global market and domestic branded Formulation. It’s majorly into Active Pharmaceutical Ingredient (API) Sales & Marketing in over 50 countries and Pan-India
Formulation presence